Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Questions To Ask Your Health Care Provider

• I have metastatic breast cancer and a BRCA mutation; should I consider treatment with a PARP inhibitor?
• What are the risks and benefits of treatment with a PARP inhibitor?
• I have a personal or family history of cancer, but I have not had genetic testing; should I consider having genetic testing?
• I have metastatic breast cancer and an inherited mutation in a gene that is not BRCA1 or BRCA2; are there any therapies or clinical trials that I should consider?
• Should I have tumor biomarker testing to see which treatment would be most useful for treating my metastatic breast cancer?
• As a person with an inherited mutation in a DNA damage response gene, what other cancer risks should I be aware of?

Open Clinical Trials

The following studies look at PARP inhibitors as treatment for advanced breast cancer.

• NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study tests the safety and effectiveness of the investigational treatment XL309 when used alone or in combination with a PARP inhibitor to treat people with certain advanced solid tumors including breast cancer. 
• NCT04673448: Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation. This study looks at the effectiveness of combining the PARP inhibitor niraparib and an immunotherapy dostarlimab to treating people with an inherited BRCA mutation or a tumor mutation who have metastatic or advanced cancer that cannot be removed by surgery.
• NCT04090567: Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation. The study examines how well the PARP inhibitor olaparib works in combination with cediranib or ceralasertib to reduce the size of cancer and determines the length of time patients respond well to the treatment.
• NCT04039230: Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. This project studies the effect of antibody-drug conjugate sacituzumab govitecan when combined with the PARP inhibitor talazoparib for patients with metastatic TNBC. 
• NCT03990896: Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations. This study enrolls metastatic breast cancer patients an acquired BRCA1 or BRCA2 tumor mutations found through liquid biopsy and who do not have an inherited mutation in BRCA1 or BRCA2.
• NCT04550494: Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib. This study determines the safety and effectiveness of the drug talazoparib (Talzenna) for treating people with advanced breast, gastric, ovarian, pancreatic or other solid tumors who have an inherited mutation or an acquired mutation in certain DNA repair genes, including BRCA1, BRCA2, ATM, CHEK2, PALB2 and other genes. 
• NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors. This study tests the safety and effectiveness of the experimental drug NUV-868 when given alone and in combination with a PARP inhibitor for people with advanced solid tumors.

Several other clinical trials for treating patients with metastatic breast cancer can be found here.

The following studies look at treatment for people with advanced solid tumors. 

• NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors.This study tests the safety and effectiveness of the experimental drug NUV-868 alone and combined with a PARP inhibitor in people with advanced solid tumors. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
• NCT02264678: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents. This is a study of orally administered ceralasertib combined with chemotherapy regimens and/or novel anticancer agents for patients with advanced cancer. The study enrolls people with tumors that are HRD-positive or who have inherited mutations in BRCA1, BRCA2, ATM, RAD51C or RAD51D.  
• NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). This research is designed to learn whether treatment with a new PARP inhibitor, AZD5305, used alone or in combination with anti-cancer agents is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors. The study is open to people who have previously been treated with PARP inhibitors.  
• NCT04267939: ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer. This study looks at how well people with advanced solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to people with inherited mutations in ATM, BRCA1, BRCA2 and other genes. Contact the study coordinator for information about eligibility for people with mutations in other genes. 
• NCT04657068: Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors. This study looks at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes that are linked to DNA damage repair. This study is open to people who have an inherited or acquired BRCA or ATM mutation or whose tumors are HRD-positive. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.